Discovery - University of Dundee - Online Publications

Library & Learning Centre

NT5E CpG island methylation is a favourable breast cancer biomarker

Standard

NT5E CpG island methylation is a favourable breast cancer biomarker. / Lo Nigro, C.; Monteverde, M.; Lee, S.; Lattanzio, L.; Vivenza, D.; Comino, A.; Syed, N.; McHugh, A.; Wang, H.; Proby, C.; Garrone, O.; Merlano, M.; Hatzimichael, E.; Briasoulis, E.; Gojis, O.; Palmieri, C.; Jordan, L.; Quinlan, P.; Thompson, A.; Crook, T.

In: British Journal of Cancer, Vol. 107, No. 1, 2012, p. 75-83.

Research output: Contribution to journalArticle

Harvard

Lo Nigro, C, Monteverde, M, Lee, S, Lattanzio, L, Vivenza, D, Comino, A, Syed, N, McHugh, A, Wang, H, Proby, C, Garrone, O, Merlano, M, Hatzimichael, E, Briasoulis, E, Gojis, O, Palmieri, C, Jordan, L, Quinlan, P, Thompson, A & Crook, T 2012, 'NT5E CpG island methylation is a favourable breast cancer biomarker' British Journal of Cancer, vol 107, no. 1, pp. 75-83., 10.1038/bjc.2012.212

APA

Lo Nigro, C., Monteverde, M., Lee, S., Lattanzio, L., Vivenza, D., Comino, A., ... Crook, T. (2012). NT5E CpG island methylation is a favourable breast cancer biomarker. British Journal of Cancer, 107(1), 75-83. 10.1038/bjc.2012.212

Vancouver

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A et al. NT5E CpG island methylation is a favourable breast cancer biomarker. British Journal of Cancer. 2012;107(1):75-83. Available from: 10.1038/bjc.2012.212

Author

Lo Nigro, C.; Monteverde, M.; Lee, S.; Lattanzio, L.; Vivenza, D.; Comino, A.; Syed, N.; McHugh, A.; Wang, H.; Proby, C.; Garrone, O.; Merlano, M.; Hatzimichael, E.; Briasoulis, E.; Gojis, O.; Palmieri, C.; Jordan, L.; Quinlan, P.; Thompson, A.; Crook, T. / NT5E CpG island methylation is a favourable breast cancer biomarker.

In: British Journal of Cancer, Vol. 107, No. 1, 2012, p. 75-83.

Research output: Contribution to journalArticle

Bibtex - Download

@article{80ad2323eb1549dcb69e3feeade0b37d,
title = "NT5E CpG island methylation is a favourable breast cancer biomarker",
author = "{Lo Nigro}, C. and M. Monteverde and S. Lee and L. Lattanzio and D. Vivenza and A. Comino and N. Syed and A. McHugh and H. Wang and C. Proby and O. Garrone and M. Merlano and E. Hatzimichael and E. Briasoulis and O. Gojis and C. Palmieri and L. Jordan and P. Quinlan and A. Thompson and T. Crook",
year = "2012",
doi = "10.1038/bjc.2012.212",
volume = "107",
number = "1",
pages = "75--83",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - NT5E CpG island methylation is a favourable breast cancer biomarker

A1 - Lo Nigro,C.

A1 - Monteverde,M.

A1 - Lee,S.

A1 - Lattanzio,L.

A1 - Vivenza,D.

A1 - Comino,A.

A1 - Syed,N.

A1 - McHugh,A.

A1 - Wang,H.

A1 - Proby,C.

A1 - Garrone,O.

A1 - Merlano,M.

A1 - Hatzimichael,E.

A1 - Briasoulis,E.

A1 - Gojis,O.

A1 - Palmieri,C.

A1 - Jordan,L.

A1 - Quinlan,P.

A1 - Thompson,A.

A1 - Crook,T.

AU - Lo Nigro,C.

AU - Monteverde,M.

AU - Lee,S.

AU - Lattanzio,L.

AU - Vivenza,D.

AU - Comino,A.

AU - Syed,N.

AU - McHugh,A.

AU - Wang,H.

AU - Proby,C.

AU - Garrone,O.

AU - Merlano,M.

AU - Hatzimichael,E.

AU - Briasoulis,E.

AU - Gojis,O.

AU - Palmieri,C.

AU - Jordan,L.

AU - Quinlan,P.

AU - Thompson,A.

AU - Crook,T.

PY - 2012

Y1 - 2012

N2 - Background: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. Methods: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. Results: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P=0.003, OR=0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P=0.01, OR=11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P=0.001, HR=2.7) and overall survival (OS) (P=0.001, HR=3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P=0.011, HR=3.27, 95% CI: 1.31-8.12) and in triple negative cases (P=0.004; HR=6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P=0.0016, HR=5.1, 95% CI: 1.8-14.37) and OS (P=0.0005, HR=7.4, 95% CI: 2.416-23.08). Conclusion: NT5E CpG island methylation is a promising breast cancer biomarker. © 2012 Cancer Research UK All rights reserved.

AB - Background: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the light of existing preclinical and clinical data, we studied NT5E (5'-nucleotidase, ecto) expression and NT5E CpG island methylation in breast cancer. Methods: We used RT-PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and primary and breast carcinomas. Results: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series, patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P=0.003, OR=0.34, 95% CI: 0.17-0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary tumours (P=0.01, OR=11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS) (P=0.001, HR=2.7) and overall survival (OS) (P=0.001, HR=3). The favourable prognostic value of NT5E methylation was confirmed in oestrogen receptor negative (P=0.011, HR=3.27, 95% CI: 1.31-8.12) and in triple negative cases (P=0.004; HR=6.2, 95% CI: 1.9-20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose tumours were positive for NT5E CpG island methylation: DFS (P=0.0016, HR=5.1, 95% CI: 1.8-14.37) and OS (P=0.0005, HR=7.4, 95% CI: 2.416-23.08). Conclusion: NT5E CpG island methylation is a promising breast cancer biomarker. © 2012 Cancer Research UK All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=84863004265&partnerID=8YFLogxK

U2 - 10.1038/bjc.2012.212

DO - 10.1038/bjc.2012.212

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

VL - 107

SP - 75

EP - 83

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy